Biofrontera AG: Swissmedic grants marketing approval for Ameluz® in Switzerland

Leverkusen (pta007/07.12.2015/08:00 UTC+1) Biofrontera (FSE/AIM: B8F), the biopharmaceutical company focusing on sun-induced skin cancer, announces that its Swiss partner Louis Widmer SA has received approval to market Ameluz® in Switzerland.

The submission for national approval was filed by Louis Widmer in November 2014. The decision on market authorization follows the European approval granted in 2011.

The logistics for a planned launch in spring 2016 are now being prepared. In parallel, Louis Widmer has applied for reimbursement that will be decided during the next year.

Hermann Lübbert, CEO of Biofrontera AG commented: "The approval by the Swissmedic marks another important milestone towards the global commercialization of Ameluz®, and we are delighted that the innovative photodynamic therapy with its outstanding efficacy in the treatment of actinic keratoses will be available to patients in Switzerland in the spring."

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer, +49 (0) 214 87 63 2 0
press@biofrontera.com
http://www.biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker, +49 (0) 152 08931514

Nomad and Broker: Shore Capital
Bidhi Bhoma / Toby Gibbs, +44(0) 20 7408 4090

IR UK: Seton Services
Toni Vallen, +44(0) 20 7603 6797

Financial PR: Gable Communications
John Bick, +44(0) 20 7193 7463
Justine James, +44 (0)7872 061007

Background:
Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart